SCHEMBL3701482

SCHEMBL3701482

CC(OCc1ccccc1)OC(C)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
IDO1 P14902 1/20 0.44
SLC1A3 P43003 2/20 0.43
SLC1A2 P43004 2/20 0.43
SLC1A1 P43005 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
AGXT P21549 1/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
RCE1 Q9Y256 1/20 0.41
SLC6A2 P23975 3/20 0.41
TAAR1 Q96RJ0 3/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236137 0.94 RCE1 (0.45) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL9278231 0.92 TSHR (0.41) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL14094034 0.91 TSHR (0.44) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL1571975 0.91 TSHR (0.52) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL15518976 0.88 SLC1A3 (0.42) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL17697790 0.88 RCE1 (0.44) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL10967316 0.88 TSHR (0.41) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL7739982 0.86 RCE1 (0.38) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL683166 0.84 RCE1 (0.47) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL23855801 0.83 IDO1 (0.52) TSHRIDO1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154181-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2025-05-15 US disclosed
US-12173021-B2 Treprostinil prodrugs UNITED THERAPEUTICS CORPORATION (US) 2024-12-24 US disclosed
US-20240051979-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2024-02-15 US disclosed
US-11634443-B2 Treprostinil prodrugs UNITED THERAPEUTICS CORPORATION (US) 2023-04-25 US disclosed
EP-4017588-A1 TREPROSTINIL PRODRUGS United Therapeutics Corporation (US) 2022-06-29 EP disclosed
CN-114616225-A Treprostinil prodrugs 联合治疗公司 2022-06-10 CN disclosed
WO-2021041320-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2021-03-04 WO disclosed
US-20210054009-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2021-02-25 US disclosed
US-9017726-B2 Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-04-28 US disclosed
US-20140031289-A1 POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-01-30 US disclosed
US-20120121517-A1 BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF Korean Institute of Science and Technology of Seoul, Republic of Korea 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154181-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 TSHR 1445/4885IDO1 2968/4885SLC1A3 637/4885
US-20120121517-A1 BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF PHOSPHO1, HSPA2, FEM1B TSHR 929/4885IDO1 2168/4885SLC1A3 3872/4885
US-20210054009-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 TSHR 1445/4885IDO1 2968/4885SLC1A3 637/4885
US-20140031289-A1 POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF PHOSPHO1, PLCB3, INPP5D TSHR 3450/4885IDO1 2965/4885SLC1A3 3062/4885
US-20240051979-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 TSHR 1445/4885IDO1 2968/4885SLC1A3 637/4885
US-12173021-B2 Treprostinil prodrugs TYMP, TK1, DCTPP1 TSHR 1445/4885IDO1 2968/4885SLC1A3 637/4885
US-11634443-B2 Treprostinil prodrugs TYMP, TK1, DCTPP1 TSHR 1445/4885IDO1 2968/4885SLC1A3 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.